research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research THE ROLE Of 5αR AND α1AR INHIBITORS IN MANAGEMENT OF BPH
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Les Visiteurs des malades
5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
research Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.
research Plasma androsterone/epiandrosterone sulfates as markers of 5α-reductase activity: Effect of finasteride in normal men
Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
research Dutasteride/finasteride
research 5α‐Reductase Inhibitors
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
research Azasteroids as inhibitors of testosterone 5α-reductase in mammalian skin
Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research New Drugs: Dutasteride
Dutasteride is approved to help manage prostate enlargement.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research Effect of 5α-reductase inhibitors on sexual function: New contributions
5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
research 5 Alpha-reductase inhibitors: whatʼs new?
A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
research Table_1.docx
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Hormonal manipulation of benign prostatic hyperplasia
Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
research Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
research Acute urinary retention: risks and management.
Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
research Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
research Triple Hormonal Blockade (ADT3): A Patient’s Perspective
Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
research Testosterone replacement in the setting of Finasteride therapy: a therapeutic dilemma
research Bladder cancer survival in men using 5-alpha-reductase inhibitors
Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
research Table_2.docx
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.